Minocycline and the risk of acute psychiatric events in adolescence: A self-controlled case series

Abstract

Background

Minocycline has neurological anti-inflammatory properties and has been hypothesised to have antipsychotic effects.

Aim

The aim of this study was to investigate, using routinely collected United Kingdom primary health care data, whether adolescent men and women are more or less likely to receive an urgent psychiatric referral during treatment for acne with minocycline compared with periods of non-treatment.

Method

A self-controlled case series using United Kingdom Clinical Practice Research Datalink to calculate the incidence rate ratio of urgent psychiatric referrals for individuals, comparing periods during which minocycline was prescribed with unexposed periods, adjusted for age.

Results

We found 167 individuals who were at the time exposed to minocycline for a mean of 99 days and who received an urgent psychiatric referral. There was no difference in psychiatric referral risk during periods of exposure compared with periods of non-exposure: incidence rate ratio first 6 weeks of exposure 1.96, 95% confidence interval 0.82–4.71, p=0.132; incidence rate ratio remaining exposure period=1.97, 95% confidence interval 0.86–4.47, p=0.107.

Conclusions

We found no evidence in support of a protective effect of minocycline against severe psychiatric symptoms in adolescence.

Keywords

Schizophrenia acute psychiatric referral tetracycline

Get full access to this article

View all access options for this article.

References

Chaudhry

Hallak

Husain

et al . (2012) Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 26: 1185–1193.

Dean

Maes

Ashton

et al . (2014) Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: A double blind, randomised, placebo controlled trial. Clin Psychopharmacol Neurosci 12: 180–188.

Farrington

(2004) Control without separate controls: Evaluation of vaccine safety using case-only methods. Vaccine 22: 2064–2070.

Farrington

Nash

Miller

(1996) Case series analysis of adverse reactions to vaccines: A comparative evaluation. Am J Epidemiol 143: 1165–1173.

Garcia Rodriguez

Perez Gutthann

(1998) Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45: 419–425.

Garner

Eady

Bennett

et al . (2012) Minocycline for acne vulgaris: Efficacy and safety. Cochrane Database Syst Rev 8: CD002086.

Herrero-Zazo

Brauer

Gaughran

et al . (2017) Examining the potential preventative effects of minocycline prescribed for acne on the incidence of severe mental illnesses: A historical cohort study. J Psychopharmacol 32: 559–556.

Herrett

Thomas

Schoonen

et al . (2010) Validation and validity of diagnoses in the General Practice Research Database: A systematic review. Br J Clin Pharmacol 69: 4–14.

Husain

Chaudhry

Rahman

et al . (2015) Minocycline as an adjunct for treatment-resistant depressive symptoms: Study protocol for a pilot randomised controlled trial. Trials 16: 410.

10.

Kelly

Sullivan

McEvoy

et al . (2015) Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol 35: 374–381.

11.

Lamberg

(1998) Acne drug depression warnings highlight need for expert care. JAMA 279: 1057.

12.

Levkovitz

Levi

Braw

et al . (2007) Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res 1154: 154–162.

13.

Levkovitz

Mendlovic

Issaki

et al . (2008) Minocycline amilorates negative symptoms and cognitive deficits in early-phase schizophrenia: A double-blind, randomized placebo-controlled study. Schizophr Res 98: 14.

14.

Levkovitz

Mendlovich

Riwkes

et al . (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 71: 138–149.

15.

Miyaoka

Yasukawa

Yasuda

et al . (2007) Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31: 304–307.

16.

Miyaoka

Yasukawa

Yasuda

et al . (2008) Minocycline as adjunctive therapy for schizophrenia: An open-label study. Clin Neuropharmacol 31: 287–292.

17.

Monte

de Souza

McIntyre

et al . (2013) Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways. J Psychopharmacol 27: 1032–1043.

18.

Whitaker

Farrington

Spiessens

et al . (2006) Tutorial in biostatistics: The self-controlled case series method. Stat Med 25: 1768–1797.